Literature DB >> 10381057

Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes.

F J Blanco1, R Guitian, J Moreno, F J de Toro, F Galdo.   

Abstract

OBJECTIVE: To study the effect of steroidal and nonsteroidal antiinflammatory drugs (NSAID) on cyclooxygenase (COX-1 and COX-2) activity in human articular chondrocytes.
METHODS: Chondrocytes were isolated from articular cartilage of donors with no articular disease. Unstimulated and interleukin 1 (IL-1) stimulated chondrocytes were used as models to study the effects of drugs on COX-1 and COX-2. Cells were incubated with vehicle or drugs; supernatants were removed and the level of prostaglandin E2 (PGE2) in each sample was determined by enzyme immunoassay. IC50 were calculated from the reduction in PGE2 content by different concentrations of the test substance by linear regression analysis.
RESULTS: COX- mRNA was detected in unstimulated cells, but stimulation with IL-1 for up 12 h did not modify the levels of COX-1 mRNA. In contrast, COX-2 mRNA was not detectable in unstimulated cells, but it was induced by IL-1. Dexamethasone inhibited COX-2 mRNA expression induced by IL-1. COX-2 protein levels correlated with mRNA expression. Dexamethasone was the strongest drug inhibitor of COX-2 (IC50 = 0.0073 microM). However, it did not inhibit COX-1 activity. Among all NSAID tested, meloxicam and aspirin were the least potent inhibitors of COX-1 (IC50 = 36.6 microM and 3.57 microM, respectively). Indomethacin and diclofenac were the most potent inhibitors of COX-1 (IC50 = 0.063 microM and 0.611 microM, respectively) and COX-2 isoforms (IC50 = 0.48 microM and IC50 = 0.63 microM, respectively). Meloxicam was a more potent inhibitor of COX-2 (IC50 = 4.7 microM) than aspirin (IC50 = 29.3 microM) and similar to piroxicam (IC50 = 4.4 microM). Among all drugs tested dexamethasone showed the greatest selectivity for COX-2 and meloxicam was the NSAID with the best COX-2/COX-1 ratio (r = 0.12). Aspirin and piroxicam were about 8 times more active against COX-1 than COX-2, indomethacin was 7 times more active, and diclofenac was an equipotent inhibitor of COX-1 and COX-2.
CONCLUSION: We found that COX-1 and COX-2 isoforms are expressed in human chondrocytes at rest and in IL-1 stimulated cells, respectively. Antiinflammatory drugs have different capacities to inhibit COX enzyme in human articular chondrocytes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10381057

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  24 in total

1.  Curcumin synergizes with resveratrol to stimulate the MAPK signaling pathway in human articular chondrocytes in vitro.

Authors:  Mehdi Shakibaei; Ali Mobasheri; Constanze Buhrmann
Journal:  Genes Nutr       Date:  2010-05-25       Impact factor: 5.523

2.  Prostacyclin regulates bone growth via the Epac/Rap1 pathway.

Authors:  Michele R Hutchison; Perrin C White
Journal:  Endocrinology       Date:  2014-11-18       Impact factor: 4.736

3.  Anti-Ulcer Efficacy of Soluble Epoxide Hydrolase Inhibitor TPPU on Diclofenac-Induced Intestinal Ulcers.

Authors:  Sumanta Kumar Goswami; Debin Wan; Jun Yang; Carlos A Trindade da Silva; Christophe Morisseau; Sean D Kodani; Guang-Yu Yang; Bora Inceoglu; Bruce D Hammock
Journal:  J Pharmacol Exp Ther       Date:  2016-03-17       Impact factor: 4.030

4.  NSAID use in intervertebral disc degeneration: what are the effects on matrix homeostasis in vivo?

Authors:  Nicholas Vaudreuil; Tiffany Kadow; Takashi Yurube; Robert Hartman; Kevin Ngo; Qing Dong; Pedro Pohl; J Paulo Coelho; James Kang; Nam Vo; Gwendolyn Sowa
Journal:  Spine J       Date:  2017-04-14       Impact factor: 4.166

5.  Biological effects of the plant-derived polyphenol resveratrol in human articular cartilage and chondrosarcoma cells.

Authors:  Hee-Jeong Im; Xin Li; Di Chen; Dongyao Yan; Jaesung Kim; Michael B Ellman; Gary S Stein; Brian Cole; Ranjan Kc; Gabriella Cs-Szabo; Andre J van Wijnen
Journal:  J Cell Physiol       Date:  2012-10       Impact factor: 6.384

6.  Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to CYP2C9 genetic polymorphism.

Authors:  Chang-Keun Cho; Pureum Kang; Hye-Jung Park; Eunvin Ko; Chou Yen Mu; Yun Jeong Lee; Chang-Ik Choi; Hyung Sik Kim; Choon-Gon Jang; Jung-Woo Bae; Seok-Yong Lee
Journal:  Arch Pharm Res       Date:  2022-05-31       Impact factor: 4.946

7.  Cyclooxygenase-1-dependent prostaglandins mediate susceptibility to systemic inflammation-induced acute cognitive dysfunction.

Authors:  Éadaoin W Griffin; Donal T Skelly; Carol L Murray; Colm Cunningham
Journal:  J Neurosci       Date:  2013-09-18       Impact factor: 6.167

8.  Anti-tumor effect of non-steroidal anti-inflammatory drugs on human ovarian cancers.

Authors:  Bing Xin; Yoshihito Yokoyama; Tatsuhiko Shigeto; Hideki Mizunuma
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

9.  Malvidin attenuates pain and inflammation in rats with osteoarthritis by suppressing NF-κB signaling pathway.

Authors:  Teng Dai; Keqing Shi; Gang Chen; Yimin Shen; Ting Pan
Journal:  Inflamm Res       Date:  2017-08-29       Impact factor: 4.575

10.  Evidence for cyclooxygenase-2 association with caveolin-3 in primary cultured rat chondrocytes.

Authors:  Jin-Oh Kwak; Woon Kyu Lee; Hyun-Woo Kim; Sun-Mi Jung; Kwang-Jin Oh; Sang-Yong Jung; Yang Hoon Huh; Seok Ho Cha
Journal:  J Korean Med Sci       Date:  2006-02       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.